102 research outputs found
Autoimmune response following influenza H1N1 vaccination in patients with juvenile idiopathic arthritis
Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
Objectives. To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under infliximab were included. None had dyslipoproteinemia or previous statin use. Total cholesterol (TC) and its fractions, inflammatory markers, and prednisone use were evaluated. Results. The comparisons of lipid levels between baseline and after three months (3M) of anti-TNF therapy showed that there was a significant increase in mean triglycerides (117.8 ± 49.7 versus 140.1 ± 64.1 mg/dL, P = 0.028) and VLDL-c (23.6 ± 10.5 versus 28.4 ± 13.7 mg/dL, P = 0.019) levels. In contrast, there were no differences in the mean TC (P = 0.28), LDL-c (P = 0.42), and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P > 0.05). Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604, P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients after three months
Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate?
Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
OBJECTIVE: Immunosuppressed patients are at risk of microsporidiosis, and this parasitosis has an increased rate of dissemination in this population. Our objective was to evaluate the presence of microsporidiosis and other intestinal parasites in rheumatic disease patients undergoing anti-tumor necrosis factor/disease-modifying anti-rheumatic drug treatment. METHODS: Ninety-eight patients (47 with rheumatoid arthritis, 31 with ankylosing spondylitis and 11 with psoriatic arthritis) and 92 healthy control patients were enrolled in the study. Three stool samples and cultures were collected from each subject. RESULTS: The frequency of microsporidia was significantly higher in rheumatic disease patients than in control subjects (36 vs. 4%, respectively; p<0.0001), as well as in those with rheumatic diseases (32 vs. 4%, respectively; p<0.0001), ankylosing spondylitis (45 vs. 4%, respectively; p<0.0001) and psoriatic arthritis (40 vs. 4%, respectively; p<0.0001), despite a similar social-economic class distribution in both the patient and control groups (p = 0.1153). Of note, concomitant fecal leukocytes were observed in the majority of the microsporidia-positive patients (79.5%). Approximately 80% of the patients had gastrointestinal symptoms, such as diarrhea (26%), abdominal pain (31%) and weight loss (5%), although the frequencies of these symptoms were comparable in patients with and without this infection (p>0.05). Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis disease activity parameters were comparable in both groups (p>0.05). The duration of anti-tumor necrosis factor/disease-modifying anti-rheumatic drugs and glucocorticoid use were also similar in both groups. CONCLUSION: We have documented that microsporidiosis with intestinal mucosa disruption is frequent in patients undergoing concomitant anti-tumor necrosis factor/disease-modifying anti-rheumatic drug therapy. Impaired host defenses due to the combination of the underlying disease and the immunosuppressive therapy is the most likely explanation for this finding, and this increased susceptibility reinforces the need for the investigation of microsporidia and implementation of treatment strategies in this population.FAPESPCNPQFederico FoundationWyet
Caracterização do perfil dos piscicultores do lago de Sobradinho e região.
Através de questionário socioeconômico, foi caracterizado o sistema de produção de tilápia em tanques-rede no entorno do lago de Sobradinho-BA. Desta forma, foi realizado um levantamento em 2017, onde 15 áreas de produção na forma de produtores individuais ou de associações participaram. Desse grupo, três associações existentes permanecem no local desde 2004. A área produtiva estimada é de aproximadamente 10.000 m³, onde metade dos produtores utiliza tanques-rede de 4m³, embora 1/3 deles já trocaram esses pequenos tanques por maiores que medem 18m³ ou 25m³. Ao analisar o tempo de atividade e a produtividade anual dessa região, afirma-se que os produtores locais já dominam técnicas de cultivo de tilápia em tanques-redes. Os mesmos conseguem identificar quais os melhores fornecedores de alevinos e escolher rações que proporcionam melhore desempenho ou custo-benefício. Foi relatado por 100% dos produtores entrevistados que a falta do licenciamento ambiental é o principal entrave da produção, impossibilitando o investimento bancário. A maior parte dos produtores não vive exclusivamente da piscicultura, conciliando outras atividades como, por exemplo, cargos públicos. Contudo, a produção de tilápia (Oreochromis niloticus) em tanques-rede no lago de Sobradinho é uma atividade rentável e que já formou uma cadeia produtiva na região, gerando benefícios em vários setores. No entanto, o licenciamento ambiental que dificulta o acesso ao crédito bancário tem sido uma grande dificuldade para a expansão dessa atividade promissora para a região
Chemical-bromatological composition of silages from biomass sorghum genotypes.
The biomass sorghum [Sorghum bicolor (L.) Moench] was developed for energy production, but its agronomic characteristics make it an alternative plant for silage production. This study aimed to evaluate the chemical-bromatological composition of silages from biomass sorghum genotypes. The experimental genotypes B004, B005, B009, B010, B011, B013, B015 and B020, as well as three commercially available genotypes (BRS655, Volumax and K1009), were evaluated. The pH, dry matter, ash, organic matter, crude protein, neutral detergent fiber, acid detergent fiber, hemicellulose and lignin were analyzed. A completely randomized design, with four replications, was used, having the genotypes as treatments. Although significant differences were observed among the 11 genotypes, the chemical-bromatological composition of all them showed their potential to be used for silage production
2021 DORIS definition of remission in SLE: final recommendations from an international task force
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies
Third brazilian consensus for autoantIbodies screening in HEp-2 Cells : historical perspectve, quality control and clinical associatons
O III Consenso Brasileiro para Pesquisa de Autoanticorpos em Células HEp-2 (FAN) objetivou discutir
estratégias para controlar a qualidade do ensaio, promover a atualização das associações clínicas dos diversos
padrões e avaliar as difculdades de implantação do II Consenso ocorrido no ano de 2002. Métodos: Nos
dias 13 e 14 de abril de 2007 participaram do encontro em Goiânia pesquisadores e especialistas de diversos
centros universitários e laboratórios clínicos de diferentes regiões do Brasil, com o propósito de discutir e
aprovar as recomendações que visam a melhores padronização, interpretação e utilização do ensaio pelos
clínicos. Foram convidados como ouvintes representantes comerciais de diferentes empresas produtoras de
insumos para realização do teste de FAN. Resultados e conclusão: Dada a heterogeneidade de microscópios
e reagentes disponíveis no mercado, o III Consenso enfatizou a necessidade do controle de qualidade em
ensaios de imunofuorescência indireta. Foram também feitas algumas adequações na terminologia utilizada
para classifcar os diferentes padrões. Finalmente, foi realizada uma atualização das associações clínicas com
fnalidade de facilitar cada vez mais o melhor uso do ensaio pelos clínicos. _________________________________________________________________________________ ABSTRACTThe Third Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells (ANA) had as purpose the
evaluation of diffculties in the accomplishment of the 2nd Consensus recommendations that took place in the
year of 2002, the discussion of strategies for quality control of the assay and the discussion of an update of the
clinical associations of the several immunofuorescent patterns. Methods: Several ANA experts from university
centers and private laboratories in different areas in Brazil joined the workshop in Goiânia on 2007 April 13
and 14 with the purpose of discussing and approving the recommendations for standardization, interpretation
and use of the test by physicians. Commercial representatives of different ANA slide brands were also invited as
listeners to the workshop. Results and conclusion: The 3rd ANA Consensus emphasized the need for quality
control in indirect immunofuorescent assays since there is a considerable heterogeneity of available microscopes
and reagents. It also promoted adaptations in the previously approved terminology used to classify the different
patterns and fnally updated the clinical associations of the several patterns with the purpose of providing
guidance for interpretation of the assay by clinical pathologists and assistant physicians
Third Brazilian consensus for autoantibodies screening in HEp-2 cells (ANA) : recommendations for standardization of autoantibodies screening trial in HEp-2 cells, quality control and clinical associations
Objetivo: O 3º Consenso Brasileiro para pesquisa de autoanticorpos em Células HEp-2 (FAN) teve como propósito
avaliar as dificuldades de implantação do 2º Consenso ocorrido no ano de 2002, discutir estratégias para controlar a
qualidade do ensaio e promover a atualização das associações clínicas dos diversos padrões. Métodos: Participaram do
encontro em Goiânia nos dias 13 e 14 de abril de 2008 pesquisadores e especialistas de diversos centros universitários e
laboratórios clínicos de diferentes regiões do Brasil, com o propósito de discutir e aprovar as recomendações que visam à
melhor padronização, interpretação e utilização do ensaio pelos clínicos. Representantes comerciais de diferentes empresas
produtoras de insumos para realização do teste de FAN foram convidados como ouvintes. Resultados e Conclusões:
O 3º Consenso enfatizou a necessidade do controle de qualidade em imunofluorescência dada a heterogeneidade de
microscópios e reagentes disponíveis no mercado, promoveu adequações na terminologia utilizada para classificar os
diferentes padrões e, finalmente, atualizou as associações clínicas com finalidade de facilitar cada vez mais o melhor
uso do ensaio pelos clínicos. ________________________________________________________________________________ ABSTRACTObjective: The Third Brazilian Consensus for autoantibodies Screening in HEp-2 cells had as purpose the evaluation
of difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, the
discussion of strategies for quality control of the assay and the promotion of an update of the clinical associations of
the several immunofluorescent patterns. Methods: Several ANA experts from university centers and private laboratories
in different areas in Brazil joined the workshop in Goiânia on 2008 April 13 and 14 with the purpose of discussing
and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial
representatives of different ANA slide brands were also invited as listeners to the workshop. Results and Conclusions:
The 3rd Consensus emphasized the need for quality control in indirect immunofluorescent since there is a considerable
heterogeneity of available microscopes and reagents. It also promoted adaptations in the previously approved terminology
used to classify the different patterns and finally updated the clinical associations of the several patterns with the
purpose of providing guidance for interpretation of the assay by clinical pathologists and assistant physicians
- …